The state of New Jersey currently has 408 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
NCT00823654
Recruiting
The purpose of this study is to see how the cancer treatment affects the ovaries. Cancer treatment can make it hard for a person to conceive a child in the future. It may also bring on early menopause. We will check blood levels of hormones that the ovaries produce. We will do this before, during, and after the cancer treatment. We will also ask the patient to fill out questionnaires about their menstrual cycle (periods) and information about your health and pregnancies. This may help us learn w... Read More
Gender:
FEMALE
Ages:
Between 18 years and 44 years
Trial Updated:
04/10/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +2 locations
Conditions: Breast Cancer
Register for Updates
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT06540066
Recruiting
This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of BGB-B3227, a humanized immunoglobulin G1 (IgG1) antibody. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-B3227 as a monotherapy or in combination with tislelizumab with or without chemotherapy in participants with selected advanced or metastatic solid tumors. The study will also identify recommended d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer, Metastatic Solid Tumor
Register for Updates
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
NCT05873205
Recruiting
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Blood Cancer, Refractory Immune Cytopenias
Register for Updates
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
NCT05318573
Recruiting
To confirm a recommended Phase 2 dose (RP2D) of FF-10832 (Gemcitabine Liposome Injection) given intravenously Day 1 of a 21-day cycle, in combination with 200 mg pembrolizumab given intravenously Day 1 of the same 21-day cycle, for treatment of advanced urothelial and non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Atlantic Health System / Morristown Medical Center, Morristown, New Jersey
Conditions: Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer
Register for Updates
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
NCT05211895
Recruiting
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Research Site, East Brunswick, New Jersey +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT06099769
Recruiting
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple negative breast cancer (TNBC) or estrogen receptor-low breast cancer (ER-low BC), and whether these study treatments work as well as standard chemotherapy with carboplatin, paclitaxel, capecitabine, or eribulin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491
Recruiting
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/09/2025
Locations: The John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Register for Updates
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
NCT04774419
Recruiting
This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activites), Basking Ridge, New Jersey +2 locations
Conditions: Endometrial Cancer
Register for Updates
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162
Recruiting
The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.
Gender:
FEMALE
Ages:
Between 50 years and 74 years
Trial Updated:
04/08/2025
Locations: Carol G. Simon Cancer Center / Atlantic Health, Morristown, New Jersey
Conditions: Ovarian Cancer
Register for Updates
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
NCT06007937
Recruiting
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or D... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey +1 locations
Conditions: Non Small Cell Lung Cancer, Metastatic, Recurrent
Register for Updates
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT06110793
Recruiting
The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Metastatic Breast Cancer
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: AtlantiCare Health Park-Cape May Court House, Cape May Court House, New Jersey +5 locations
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates